Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 14, Number 6—June 2008


High Failure Rates of Melarsoprol for Sleeping Sickness, Democratic Republic of Congo

Jo Robays*Comments to Author , Gaspard Nyamowala†‡, Claude Sese†, Victor Betu Ku Mesu Kande†, Pascal Lutumba†§, Wim Van der Veken¶, and Marleen Boelaert*
Author affiliations: *Institute of Tropical Medicine, Antwerp, Belgium; †Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of Congo; ‡Medische Missie Samenwerking Organisation, Kinshasa; §University of Kinshasa, Kinshasa; ¶Belgian Technical Cooperation, Kinshasa;

Main Article

Table 2

Characteristics of 959 patients who experienced relapse after treatment 
with melarsoprol, Equateur Nord Province, 2001–2003

Characteristic No. (%)
M 433 (45.2)
526 (54.8)
>1–11mo 1 (0.1)
12–59 mo 13 (1.4)
5–59 y 936 (97.6)
>60 y
9 (0.9)
Stage of disease
First 46 (4.8)
Second 782 (81.5)
131 (13.7)
Parasites found 259 (27.0)

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO